Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Magagnoli

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
The Oncologist|May 22, 2012
Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphomaMichele Spina, Monica Balzarotti, Lilj Uziel, et al.
The Oncologist|July 27, 2019
Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet NeedsMatthew J Matasar, Stefano Luminari, Paul M Barr, et al.
British Journal of Haematology|March 29, 2014
Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study GroupAnnarita Conconi, Markus Raderer, Silvia Franceschetti, et al.
British Journal of Haematology|April 25, 2022
Chemotherapy after PD-1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamicsEleonora Calabretta, Anna Guidetti, Francesca Ricci, et al.
Nature Communications|March 14, 2023
BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomasVictor Moreno, Maria Vieito, Juan Manuel Sepulveda, et al.
Leukemia & Lymphoma|February 17, 2016
B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL)Monica Balzarotti, Ercole Brusamolino, Emanuele Angelucci, et al.
Hematological Oncology|August 4, 2017
FarmaREL: An Italian pharmacovigilance project to monitor and evaluate adverse drug reactions in haematologic patientsNicola S Fracchiolla, Silvia Artuso, Agostino Cortelezzi, et al.
Leukemia|January 18, 2023
Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II studyAnnalisa Chiappella, Anna Dodero, Andrea Evangelista, et al.
Leukemia|March 4, 2021
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphomaReid W Merryman, Luca Castagna, Laura Giordano, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
The Oncologist|May 22, 2012
Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphomaMichele Spina, Monica Balzarotti, Lilj Uziel, et al.
The Oncologist|July 27, 2019
Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet NeedsMatthew J Matasar, Stefano Luminari, Paul M Barr, et al.
British Journal of Haematology|March 29, 2014
Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study GroupAnnarita Conconi, Markus Raderer, Silvia Franceschetti, et al.
British Journal of Haematology|April 25, 2022
Chemotherapy after PD-1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamicsEleonora Calabretta, Anna Guidetti, Francesca Ricci, et al.
Nature Communications|March 14, 2023
BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomasVictor Moreno, Maria Vieito, Juan Manuel Sepulveda, et al.
Leukemia & Lymphoma|February 17, 2016
B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL)Monica Balzarotti, Ercole Brusamolino, Emanuele Angelucci, et al.
Hematological Oncology|August 4, 2017
FarmaREL: An Italian pharmacovigilance project to monitor and evaluate adverse drug reactions in haematologic patientsNicola S Fracchiolla, Silvia Artuso, Agostino Cortelezzi, et al.
Leukemia|January 18, 2023
Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II studyAnnalisa Chiappella, Anna Dodero, Andrea Evangelista, et al.
Leukemia|March 4, 2021
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphomaReid W Merryman, Luca Castagna, Laura Giordano, et al.
Pageof 4